Therefore, future development of GRPR-targeted radiotherapeutic agents should focus on not only improving tumor absorbed dose to enhance treatment efficacy, but also increasing the tumor/pancreas absorbed dose ratio to minimize potential toxicity to the pancreas. This evidence concerns the gene GRPR and neoplasm.